Key Elements of ICH Q7A GMPs for Active Pharmaceutical Ingredients
The International Conference on Harmonization (ICH) has created a standard known as ICH Q7A for Good Manufacturing Practices (GMPs) for Active Pharmaceutical Ingredients (APIs). In order to help API manufacturers apply GMPs for the creation of high-quality APIs, it was initially released in 2000.
An overview of ICH Q7A GMPs for Active Pharmaceutical Ingredients, including its scope, essential components, and implementation criteria, is the goal of this article.
Scope
The manufacturing of APIs used in human drug products is subject to the ICH Q7A guideline. It covers all phases of the production process for APIs, including raw materials, steps in the middle, and completed goods. The goal of the standard is to guarantee that APIs are consistently made and uphold the high quality criteria necessary for their intended application.
Key Elements
To guarantee the excellent quality of their goods, API manufacturers must abide by the principles and recommendations of the ICH Q7A guideline. Key components of the recommendation include:
Quality Management:
The recommendation underlines the value of quality management programmes in the creation of APIs. Manufacturers are required to set up and maintain a quality management system that addresses all facets of API production, including staff, infrastructure, tools, and records. To guarantee that APIs are developed consistently and adhere to the necessary quality standards, the quality management system must be created.
Personnel:
The guideline outlines the education and experience prerequisites for employees working on API production. The maintenance of product quality requires that manufacturers make sure their staff is properly qualified, well-trained, and aware of the significance of their job.
Facilities and Equipment:
The recommendation offers advice on the planning, building, and upkeep of structures and machinery used in API production. Facilities and equipment must be validated to guarantee that they work as intended, be properly maintained, and be acceptable for the use for which they were designed.
Documentation:
The recommendation stresses how critical accurate and thorough documentation is to the creation of APIs. All aspects of API production, including the identification and origin of raw materials, the manufacturing procedure, and the testing and release of completed goods, must be completely and accurately documented by manufacturers.
Production:
The guideline offers instructions on how to manufacture APIs, including how to use suitable starting materials, regulate crucial process variables, and validate the manufacturing process. Manufacturers are responsible for ensuring that APIs are regularly generated and fulfil the necessary quality requirements.
Quality Control:
The guideline outlines the criteria for API quality control testing. To ensure that their products satisfy the necessary quality standards, manufacturers must set up and manage a quality control system that involves testing of raw materials, materials used during production, and final goods.
Stability:
The guideline provides guidance on the stability testing of APIs. Manufacturers must conduct stability testing to demonstrate that APIs remain within their specified quality attributes throughout their shelf life.
Implementation Requirements
Although the ICH Q7A standard is commonly regarded as a best practise in API development, it is not legally required. Although following the recommendation is optional, firms who do so are more likely to comply with regulatory criteria for the creation of APIs.
Manufacturers must first set up a quality management system that encompasses every facet of API production in order to apply the guideline. To guarantee that APIs are developed consistently and adhere to the necessary quality standards, the quality management system must be created.
Additionally, manufacturers must guarantee that everybody working on the creation of API has received the necessary training and credentials. In order for facilities and equipment used in API production to be fit for their intended use, they must be carefully planned, built, and maintained.
All aspects of API production, including the identification and provenance of raw materials, the manufacturing procedure, and the testing and release of completed goods, must be accurately and completely documented by manufacturers. To guarantee that APIs are manufactured consistently and adhere to the necessary quality requirements, the manufacturing process must be validated.
Ex-FDA experts recommended training programs
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) - Recent guidance on method validation and transfer has been produced by FDA and EMA, and USP has guidance chapters on method validation, verification and transfer, equivalence testing and statistical evaluation. Articles in US Pharmacopeial Forum have introduced the concepts of measurement uncertainty and lifecycle management for analytical procedures. Lifecycle management has also been the subject of recent FDA and ICH publications.
Lifecycle Management of Analytical Methods and Procedures according to new USP and ICH Guidelines - Learn about the regulatory background and recommendations for managing the lifecycle of analytical methods and procedures. Understand current and future industry trends: the concept of lifecycle management of analytical methods, recent ICH guidance (ICH Q12), proposed USP General Chapter <1220> (Analytical Procedure Lifecycle) and Quality by Design (QbD) principles for method development and validation.
Process Validation Guidance Requirements (FDA and EU Annex 15: Qualifications and Validation) - The Process Validation Guidelines (January 2011) and the EU Annex 15: Qualification and Validation (October 2015) outline the general principles and approaches the two regulatory bodies consider appropriate elements of process validation for the manufacture of human and animal drugs and biological products, including Active Pharmaceutical Ingredients (APIs).
Managing Microbiological Out of Specification (OOS) and Out of Trend (OOT) Results in Sterile and Non-Sterile Production FDA & ICH Expectations and Guidance - The objective of this webinar is to explore the management of OOS practices and suggested avenues to take to minimize deviations, OOT, OOS and CAPA and how to attack these situations should they occur. It is also designed to determine how FDA and ICH regulations and guidances may impact them. It will also reference the new PDA TR 88, “Microbial Data Deviation Investigations in the Pharmaceutical Industry”.
Understanding and Preparing for FDA Pharmaceutical Inspections - This webinar will focus on the current trends in FDA Inspections and guidelines and how this information can be utilized to provide a foundation for compliance with the latest quality and regulatory requirements. Attendees will learn how to proactively prepare for an inspection.
Total Organic Carbon Analysis for Cleaning Validation in Pharmaceutical Manufacturing - In this cleaning validation webinar attendees will learn the Total Organic Carbon (TOC) feasibility, method validation and transfer from the laboratory to the manufacturing floor, as well as reviewing a feasibility study of multiple, difficult to oxidise or low solubility organic compounds.
Technical Writing for the Pharmaceutical, Medical Device and Biotech Industries - This technical writing training program will offer attendees an understanding of how the reporting process supports products in research, development, and in the marketplace. This virtual session will highlight the mandates for documentation set forth by the regulators, such as the FDA, the ISO, and other governing bodies. The program will train attendees on effectively reviewing and revising documents and assessing your audience, in effect producing effective written correspondence.
Installation and Qualification of the Packaging Lines - Both the U.S. FDA and EU's MDR expect documented risk-based IQ, OQ, an PQs of medical packaging lines under U.S. FDA cGMP, EU MRD, ICH Q7 and Q9 and ISO 14971
Good Documentation Practice and Record Keeping Regulations (FDA & EMA) - Good documentation Practices (GDP) is an essential factor that needs to be closely followed by the personnel in any regulated environment as a process for a successful project completion including observations of unanticipated responses that are required to be accurately recorded and verified.
US, EU and Japan GMP Requirements: Practical ICH Area Differences, Healthcare Authority Inspection Focus - This ICH GMP 90-minute webinar will provide your company the opportunity for comprehensive understanding of ICH Drug / Biologic GMP and the nuances and differences between the three main ICH triumvirate regions (U.S. EU and Japan). It will cover the key areas of how ICH was established, it’s goals and objectives, expectations of the healthcare authorities involved and practical differences that you will experience in a GMP inspection of a facility by FDA, an EU Competent Authority or PMDA.
Risk Management of Raw Materials in a GMP Environment - The objective of this live, interactive webinar is to explore raw materials in a cGMP environment, their various regulatory requirements and how they may affect the timeline of meeting the release date of your Company’s products. Please plan to bring additional personnel to the webinar to obtain cross-Departmental training.
ICH Q7A GMPs for Active Pharmaceutical Ingredients Training Course - The ICH Q7A Guidance provides harmonized guidance regarding the manufacturing of APIs up to that point where the APIs are rendered sterile. Whenever a material is classified as an API throughout the world, it should be manufactured according to the ICH Q7A guide regardless of where it is consumed.
Eliminate the Confusion - New Requirements for Clinical Laboratories to Meet GCP - This webinar will help clinical laboratories, analyzing samples from clinical trials, understand the compliance requirements concerning ICH GCP for FDA and EMA compliance.
Good Documentation Guideline (Chapter <1029> USP) - This webinar will familiarize participants with USP Chapter <1029> on good documentation guidelines. This session will wrap up the general concept and will provide information as to what needs to be documented in certain records.
The Impact of ICH E6 R2 - This webinar will discuss the overall impact of the updated GCP ICH E6 (R2) Addendum and what this means for you, your company and selected vendors.
Auditing API Facilities: A MUST to properly prepare for an FDA Regulatory API GMP Inspection - In this FDA inspection webinar attendees will learn the basic understanding of Active Pharmaceutical Ingredient Good Manufacturing Practices (ICH Q7) and the most important elements of API GMP to avoid serious deviations and failures during either a Pre-Approval or GMP Inspection.
Quality Risk Management Overview for Pharma, Biopharma and Combination Products - ICH Q9/ISO 14971 - This 90-minute webinar will cover principles and provide examples of tools for quality risk management that can be applied to different aspects of pharmaceutical quality. It will provide you with the knowledge and understanding needed to improve patient safety and also to prepare your organization for regulatory inspections.
Hazard Analysis and Risk Management under ISO 14971:2007/2012 - In this webinar attendees will learn how to develop, use and document Hazard Analysis and the Product Risk Management File and Report per ISO 14971:2007/12 and ICH Q9. Also a field-tested (US FDA and EU Notified Body) multi-industry “model” will be presented in detail.
ICH Stability Requirements and Challenges - This training program will detail the requirements for ICH stability studies, discuss how to design stability programs for your drug product, and list analytical methods requirements. It will also focus on how to interpret the data generated by the stability programs.
Good Manufacturing Practices for Active Pharmaceutical Ingredients (APIs) - This webinar will cover ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (API). Attendees will gain a deeper understanding of the importance of GMPs for APIs, apply these principles in their current roles in order to better manage quality, make improvements, solve problems and make decisions.
How to Transfer Non-Compendial and Developed QC Procedures - ICH and USP Guidelines - This webinar will explain ICH and USP guidelines for validation and how to apply ICH guidelines for method transfer and how to establish boundaries.
US, EU, Japan GMP Requirements: Practical ICH Area Differences, Healthcare Authority Inspection Focus - This 90-minute webinar will help you gain a comprehensive understanding of ICH GMPs and the nuances and differences between requirements in the US, EU and Japan. It will prepare you for regulatory inspections in these countries.
